Phasebio Pharmaceuticals Revenue Growth Rates (PHAS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Phasebio Pharmaceuticals Inc.  (NASDAQ: PHAS)
 

PHAS's Revenue Growth by Quarter and Year

Phasebio Pharmaceuticals's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PHAS Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.21
1st Quarter March 0.12
FY 0.33





PHAS Revenue second quarter 2022 Y/Y Growth Comment
Phasebio Pharmaceuticals Inc. reported drop in Revenue in the second quarter 2022 by -97.99% to $ 0.21 millions, from the same quarter in 2021.
The fall in the second quarter 2022 Phasebio Pharmaceuticals Inc.'s Revenue compares unfavorably to the Company's average Revenue growth of 1.47%.

Looking into second quarter 2022 results within Major Pharmaceutical Preparations industry 306 other companies have achieved higher Revenue growth. While Phasebio Pharmaceuticals Inc.' s Revenue meltdown of -97.99% ranks overall at the positon no. 4595 in the second quarter 2022.


PHAS Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - - - 192.31 %
3rd Quarter September - - - 380 %
2nd Quarter June -97.99 % - - -
1st Quarter March - - -50.77 % -
FY   - 3287.5 % -86.38 % -

Financial Statements
Phasebio Pharmaceuticals's second quarter 2022 Revenue $ 0.21 millions PHAS's Income Statement
Phasebio Pharmaceuticals's second quarter 2021 Revenue $ 10.34 millions Quarterly PHAS's Income Statement


PHAS Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - -52.94 % - 216.67 %
3rd Quarter September - -96.71 % - -65.71 %
2nd Quarter June 73.33 % - - 7.69 %
1st Quarter March -25 % - -57.89 % 150 %
FY (Year on Year)   - 3287.5 % -86.38 % -


Back to PHAS Growth rate Comparisons >> Back to PHAS Growth rate Comparisons >>


Revenue second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #307
Healthcare Sector #757
Overall #4595

Revenue Y/Y Growth Statistics
High Average Low
363.46 % 1.47 % -100 %
(Sep 30 2019)   (Mar 31 2021)
Revenue second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #307
Healthcare Sector #757
Overall #4595
Revenue Y/Y Growth Statistics
High Average Low
363.46 % 1.47 % -100 %
(Sep 30 2019)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Phasebio Pharmaceuticals's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
217.01 % -19.69 % -100 %
(Dec 31 2019)  


PHAS's II. Quarter Q/Q Revenue Comment
Phasebio Pharmaceuticals Inc. achieved in the II. Quarter 2022 above company average sequential Revenue jump of 73.33%, to $ 0.21 millions, from $0.12 millions in the first quarter.
PHAS is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Revenue quarter on quarter growth. While Phasebio Pharmaceuticals's Revenue growth quarter on quarter, overall rank is 321.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #76
Overall #321
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #76
Overall #321
Revenue Q/Q Growth Statistics
High Average Low
217.01 % -19.69 % -100 %
(Dec 31 2019)  


PHAS's II. Quarter Q/Q Revenue Comment
Phasebio Pharmaceuticals Inc. achieved in the II. Quarter 2022 above company average sequential Revenue jump of 73.33%, to $ 0.21 millions, from $0.12 millions in the first quarter.
PHAS is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Revenue quarter on quarter growth. While Phasebio Pharmaceuticals's Revenue growth quarter on quarter, overall rank is 321.


Phasebio Pharmaceuticals's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)
Cumulative Revenue 12 Months Ending $ 0.82 $ 10.95 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) -92.53 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 3688 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment


Phasebio Pharmaceuticals Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 219
Sector # 542
S&P 500 # 3688
Cumulative Revenue growth Comment


Phasebio Pharmaceuticals Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 219
Sector # 542
S&P 500 # 3688




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PHAS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2022
Edwards Lifesciences Corporation-0.15%$ -0.153 millions
Chemed Corporation-0.18%$ -0.182 millions
Heska Corporation-0.39%$ -0.387 millions
Ati Physical Therapy Inc -0.45%$ -0.451 millions
Phenomex Inc -0.52%$ -0.519 millions
Organon and Co -0.63%$ -0.627 millions
Outset Medical Inc -0.63%$ -0.631 millions
Accuray Incorporated-0.82%$ -0.823 millions
Travere Therapeutics Inc -0.82%$ -0.824 millions
Elite Pharmaceuticals Inc -0.84%$ -0.835 millions
Amedisys Inc-1.11%$ -1.112 millions
Teleflex Incorporated-1.25%$ -1.252 millions
Embecta Corp -1.32%$ -1.322 millions
Y mabs Therapeutics inc -1.41%$ -1.406 millions
Organogenesis Holdings Inc -1.46%$ -1.457 millions
10x Genomics Inc -1.67%$ -1.672 millions
Mimedx Group Inc -1.88%$ -1.881 millions
Acorda Therapeutics Inc -2.31%$ -2.309 millions
Community Health Systems Inc -2.43%$ -2.428 millions
Alpha Pro Tech Ltd -2.43%$ -2.432 millions
Advanced Container Technologies Inc -2.54%$ -2.539 millions
Kamada Ltd -2.68%$ -2.678 millions
Fresenius Medical Care Ag-2.73%$ -2.730 millions
Orthofix Medical Inc -2.74%$ -2.738 millions
3m Company-2.77%$ -2.771 millions
Teva Pharmaceutical Industries Limited-3.17%$ -3.171 millions
Neurometrix Inc -3.40%$ -3.397 millions
Royalty Pharma Plc-3.43%$ -3.425 millions
Bio rad Laboratories Inc -3.47%$ -3.468 millions
Healthlynked Corp-3.63%$ -3.630 millions


About Phasebio Pharmaceuticals Revenue Growth Rates (PHAS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Phasebio Pharmaceuticals Inc (CIK 1169245).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001169245-22-000093
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Phasebio Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.